Home » Stocks » NBY

NovaBay Pharmaceuticals, Inc. (NBY)

Stock Price: $0.919 USD -0.001 (-0.09%)
Updated Mar 8, 2021 12:51 PM EST - Market open
Market Cap 37.37M
Revenue (ttm) 9.75M
Net Income (ttm) -12.80M
Shares Out 40.04M
EPS (ttm) -0.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 8
Last Price $0.919
Previous Close $0.920
Change ($) -0.001
Change (%) -0.09%
Day's Open 0.944
Day's Range 0.900 - 0.950
Day's Volume 847,127
52-Week Range 0.240 - 1.940

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 6 hours ago

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals (NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova® for the eye care market and CelleRx® Clinical R...

Business Wire - 1 month ago

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $NBY #Avenova--NovaBay announces Avenova and CelleRx Clinical Reset to be available in brick-and-mortar stores.

Business Wire - 2 months ago

EMERYVILLE, Calif.--(BUSINESS WIRE)-- #Avenova--NovaBay Pharmaceuticals announces its proprietary hypochlorous acid solution has received EPA approval for SARS-CoV-2 kill claim.

Business Wire - 3 months ago

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals Expands Avenova's Geographic Reach to Australia with New Exclusive Distribution Agreement

Seeking Alpha - 3 months ago

NovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on Q3 2020 Results - Earnings Call Transcript

Business Wire - 3 months ago

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and nine months ended September 30, 2020 and provides a busines...

Business Wire - 3 months ago

EMERYVILLE, Calif.--(BUSINESS WIRE)-- #CelleRx--NovaBay Launches CelleRx Clinical Reset and enters the beauty market

Business Wire - 4 months ago

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $NBY #Avenova--NovaBay Pharmaceuticals to announce third quarter 2020 financial results on November 12

Business Wire - 4 months ago

EMERYVILLE, Calif.--(BUSINESS WIRE)-- #Avenova--NovaBay regains compliance with NYSE American listing standards

Business Wire - 5 months ago

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces expanded Avenova® consumer marketing programs designed to generate greater awareness of its a...

Business Wire - 6 months ago

EMERYVILLE, Calif.--(BUSINESS WIRE)-- #Avenova--NovaBay® Pharmaceuticals, Inc.

Business Wire - 6 months ago

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc.

Benzinga - 6 months ago

NovaBay Pharmaceuticals, Inc. (NYSE: NBY) shares are trading higher after the company announced the launch of its Avenova Facial Sanitizer on Walmart Inc.

Business Wire - 6 months ago

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay expands Avenova's online distribution to include Walmart.com

Seeking Alpha - 6 months ago

NovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on Q2 2020 Results - Earnings Call Transcript

Business Wire - 7 months ago

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay reports second quarter 2020 financial results.

InvestorPlace - 7 months ago

While penny stocks carry a high degree of risk, they could be a good place to look for value in today's market for investors that are willing to make short-term trades. These seven have potent...

Other stocks mentioned: DGLY, FRSX, IBIO, XELA, XSPA
Business Wire - 7 months ago

EMERYVILLE, Calif.--(BUSINESS WIRE)-- #Avenova--NovaBay Pharmaceuticals to Hold Second Quarter 2020 Conference Call on August 6

Seeking Alpha - 9 months ago

NovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on Q1 2020 Results - Earnings Call Transcript

Seeking Alpha - 11 months ago

NovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on Q4 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

NovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

NovaBay Pharmaceuticals' (NBY) CEO Justin Hall on Q2 2019 Results - Earnings Call Transcript

Benzinga - 1 year ago

NovaBay Pharmaceuticals (NYSE: NBY) shares are trading higher after the company said its plan of compliance was accepted by the New York Stock Exchange.

Benzinga - 1 year ago

The 875-percent rally that propelled NovaBay Pharmaceuticals, Inc. (NYSE: NBY) shares from under 50 cents to over $3 Monday came on news of the micro-cap biotech making its Avenova eyecare pro...

Market Watch - 1 year ago

NovaBay Pharmaceuticals Inc.'s stock NBY, +484.91% has blasted off to a more-than 6-fold gain in extremely active Monday afternoon trading, after the specialty pharmaceutical company said its ...

24/7 Wall Street - 1 year ago

NovaBay Pharmaceuticals Inc. (NYSE: NBY) shares absolutely exploded on Monday after the company announced that its eye care treatment would be readily available on Amazon.

Benzinga - 1 year ago

Shares of nano-cap biopharmaceutical company NovaBay Pharmaceuticals, Inc. (NYSE: NBY) skyrocketed 220 percent Monday morning after the company inked an agreement to sell its eye care product ...

Market Watch - 1 year ago

Shares of NovaBay Pharmaceuticals Inc. nearly doubled in active premarket trade Monday, after the biopharmaceutical company said its Avenova eye-care product is now available without a prescri...

Seeking Alpha - 1 year ago

NovaBay Pharmaceuticals, Inc (NBY) CEO Justin Hall on Q1 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

NovaBay Pharmaceuticals, Inc (NBY) CEO Justin Hall on Q4 2018 Results - Earnings Call Transcript

About NBY

NovaBay Pharmaceuticals, a biopharmaceutical company, develops and commercializes non-antibiotic anti-infective products to address therapeutic needs of the anti-infective market in the United States and internationally. The company offers Avenova, a solution for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye, including the eyelid; CelleRx for the aesthetic dermatology market; and NeutroPhase for the wound care market. It also develops auriclosene, a synthetic molecule for use against bact... [Read more...]

Industry
Biotechnology
IPO Date
Oct 26, 2007
CEO
Justin Hall
Employees
26
Stock Exchange
NYSEAMERICAN
Ticker Symbol
NBY
Full Company Profile

Financial Performance

In 2019, NBY's revenue was $6.60 million, a decrease of -47.24% compared to the previous year's $12.51 million. Losses were -$9.66 million, 47.6% more than in 2018.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for NBY stock is "Strong Buy." The 12-month stock price forecast is 2.63, which is an increase of 186.06% from the latest price.

Price Target
$2.63
(186.06% upside)
Analyst Consensus: Strong Buy